The following quote was from the paper below that commented on FTO inhibitors in general. How do you think Zantrene stacks up in these areas?
"few of the currently developed small-molecule FTO inhibitors are available for clinical applications due to mild bioavailability, low sensitivity, and/or poor selectivity."
https://www.mdpi.com/1422-0067/23/10/5815/pdf?version=1653299772
General Comments / Chat, page-5699
-
- There are more pages in this discussion • 5,314 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.84 |
Change
-0.025(1.34%) |
Mkt cap ! $313.3M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.91 | $1.81 | $257.6K | 138.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 26825 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 759 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |